TrialAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Long-term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension study.

María Pascual-Lucas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.